Why low evidence doesn't mean cannabis doesn't work for nerve pain

This commentary examines how recent systematic reviews, including a prominent Cochrane review, have assessed evidence for cannabis-based medicines in treating chronic neuropathic pain. While the reviews concluded that evidence certainty remains low, this analysis highlights that the interpretation of this conclusion requires careful examination. The paper argues that the methods used to evaluate the evidence—particularly the application of the GRADE framework and how studies are compared—may be influencing how results are presented to clinicians and patients, potentially leading to either overstatement or dismissal of therapeutic benefits.

The core issue centers on methodological transparency and consistency in evaluating cannabis research for neuropathic pain. Key concerns include how clinical heterogeneity (differences between study populations and designs) is handled, which outcomes researchers choose to measure, and whether studies directly apply to real-world patient populations. The commentary emphasizes that neuropathic pain is a complex and heterogeneous condition, meaning what works varies significantly between patients, making uniform assessment challenging.

The author advocates for a more balanced, context-aware interpretation of existing evidence rather than blanket dismissal based on current certainty standards. Rather than concluding cannabis-based medicines are ineffective, the commentary suggests the evidence base needs more careful, consistent application of evaluation criteria to avoid misleading both healthcare providers and patients about the actual therapeutic potential of these treatments.